Kim G. Johnson, MD

Division chief of memory disorders at Duke University.

Articles by Kim G. Johnson, MD

Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

ByKim G. Johnson, MD, R. Nolan Townsend,Sandi See Tai, MD,Isabella Ciccone, MPH

October 30th 2024

A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]

Kim G. Johnson, MD

Articles by Kim G. Johnson, MD

Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency

Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS

Evolving Landscape of Myasthenia Gravis Treatment and Unmet Needs: Leila Darki, MD

Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C

New Study to Assess Complement Inhibitor Iptacopan in Generalized Myasthenia Gravis